{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:54:26Z","timestamp":1782928466159,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ygyno.2026.01.772","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:39:54Z","timestamp":1770842394000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study"],"prefix":"10.1016","volume":"206","author":[{"given":"Prakriti","family":"Garkhail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrisia C.","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike A.","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatske M.","family":"Nieuwenhuyzen-de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2026.01.772_bb0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.ygyno.2026.01.772_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101650","article-title":"Survival after interval and delayed cytoreduction surgery in advanced ovarian cancer: a global gynaecological oncology surgical outcomes collaborative-led study (GO SOAR2)","volume":"35","author":"Gaba","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2016.04.026","article-title":"Non-surgical management of ovarian cancer: prevalence and implications","volume":"142","author":"Shalowitz","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0020","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e17","article-title":"Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery","volume":"31","author":"Liu","year":"2020","journal-title":"J. Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.01.772_bb0025","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/IGC.0b013e318247727f","article-title":"Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery","volume":"22","author":"Saha","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.01.772_bb0030","series-title":"Eierstokkanker in Nederland 2025","author":"Nederland IK","year":"2025"},{"key":"10.1016\/j.ygyno.2026.01.772_bb0035","series-title":"Cancer Treatments 2013\u20132022","author":"NDRS","year":"2025"},{"issue":"2","key":"10.1016\/j.ygyno.2026.01.772_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2018.08.041","article-title":"Disparities in treatment and survival among elderly ovarian cancer patients","volume":"151","author":"Taylor","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010072","article-title":"Unresectable ovarian cancer requires a structured plan of action: a prospective cohort study","volume":"15","author":"Nieuwenhuyzen-de Boer","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ygyno.2026.01.772_bb0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2018.02.017","article-title":"Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis","volume":"149","author":"Schuurman","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.01.772_bb0055","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2026.01.772_bb0060","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.ygyno.2026.01.772_bb0065","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.01.772_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2016.12.004","article-title":"Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - a multi-institutional cohort","volume":"144","author":"Prendergast","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2026.01.772_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e16535","article-title":"Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer","volume":"27","author":"Nayl","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2026.01.772_bb0090","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","volume":"50","author":"van der Burg","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology\/gynecologic oncology group study","volume":"144","author":"von Gruenigen","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2016.11.001","article-title":"Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: a single institution retrospective review","volume":"144","author":"Marchetti","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.01.772_bb0105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jso.26751","article-title":"Treatment outcomes and predictive factors in patients >\/=70 years old with advanced ovarian cancer","volume":"125","author":"Piedimonte","year":"2022","journal-title":"J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.01.772_bb0110","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1177\/1049909118780650","article-title":"Don\u2019t shoot the messenger: experiences of delivering prognostic information in the context of advanced cancer","volume":"35","author":"Masterson","year":"2018","journal-title":"Am. J. Hosp. Palliat. Care"},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s13187-015-0845-9","article-title":"Patients\u2019 preferences for information about the benefits and risks of second-line palliative chemotherapy and their oncologist\u2019s awareness of these preferences","volume":"31","author":"Oostendorp","year":"2016","journal-title":"J. Cancer Educ."},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2020.12.030","article-title":"Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: a systematic review","volume":"161","author":"Di Donato","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0125","first-page":"140","article-title":"ICD-O-3 terminology approved for use with cases diagnosed January 1, 2014 and after","volume":"40","author":"Fritz","year":"2013","journal-title":"J. Registry Manag."},{"issue":"5","key":"10.1016\/j.ygyno.2026.01.772_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"6","key":"10.1016\/j.ygyno.2026.01.772_bb0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Autom. Control"},{"key":"10.1016\/j.ygyno.2026.01.772_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-92","article-title":"A tutorial on sensitivity analyses in clinical trials: the what, why, when and how","volume":"13","author":"Thabane","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2026.01.772_bb0145","series-title":"R: A Language and Environment for Statistical Computing","author":"Team RC","year":"2023"},{"issue":"6","key":"10.1016\/j.ygyno.2026.01.772_bb0150","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/ijgc-2019-000489","article-title":"Treatment patterns and associated factors in patients with advanced epithelial ovarian cancer: a population-based study","volume":"29","author":"Zijlstra","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/AOG.0000000000001196","article-title":"Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995-2008","volume":"127","author":"Lin","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.01.772_bb0160","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.01.772_bb0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jgo.2016.07.008","article-title":"Ovarian cancer in the older woman","volume":"7","author":"Tew","year":"2016","journal-title":"J. Geriatr. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.01.772_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-6-42","article-title":"Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium","volume":"6","author":"Trillsch","year":"2013","journal-title":"J. Ovarian Res."},{"issue":"7","key":"10.1016\/j.ygyno.2026.01.772_bb0175","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11864-024-01205-4","article-title":"Targeted therapies in low-grade serous ovarian cancers","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.ygyno.2026.01.772_bb0180","series-title":"Consensus on Treatment for Inoperable and Peroperatively Unresectable Ovarian Cancer: A Modified Delphi Study","author":"Garkhail","year":"2025"},{"issue":"7","key":"10.1016\/j.ygyno.2026.01.772_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083270","article-title":"Examining the impact of age on chemotherapy completion in epithelial ovarian, fallopian tube and primary peritoneal cancer: a retrospective cohort study in Thailand","volume":"14","author":"Assavapokee","year":"2024","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ygyno.2026.01.772_bb0190","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol."},{"issue":"9332","key":"10.1016\/j.ygyno.2026.01.772_bb0195","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.01.772_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2023.04.029","article-title":"The most efficient and effective BRCA1\/2 testing strategy in epithelial ovarian cancer: tumor-first or germline-first?","volume":"174","author":"Witjes","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.01.772_bb0205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2015.03.052","article-title":"Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer","volume":"137","author":"Joseph","year":"2015","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:21:20Z","timestamp":1782926480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826007754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"alternative-id":["S0090825826007754"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.01.772","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.01.772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}